Education
About Us
Working with TipRanks
Follow Us
Biomx Inc. (PHGE)
:PHGE
Earnings Data
Report Date
Nov 13, 2025Before Open (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.31Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
BiomX demonstrated significant progress in its clinical pipeline, particularly with the initiation of the BX004 Phase IIb trial and positive validation from published studies. However, financial challenges were evident with a decrease in cash balance and a reported net loss, offset by cost reductions. The sentiment reflects a balanced outlook with strong clinical momentum but financial caution.Company Guidance
Initiation of BX004 Phase IIb Trial
BiomX successfully initiated patient dosing in the Phase IIb clinical trial of BX004 for cystic fibrosis patients, with top line results expected in the first quarter of 2026.
Publication in Nature Communications
Additional data from the BX004 Phase Ib/IIa study was published in Nature Communications, providing further validation of BiomX's phage therapy platform.
Positive Phase II Results for BX211
The Phase II results for BX211 showed statistically significant improvement in ulcer size reduction in diabetic foot osteomyelitis patients, with p-values of 0.046 and 0.052 at weeks 12 and 13, respectively.
Funding Support from U.S. Defense Health Agency
BiomX continues discussions with the U.S. Defense Health Agency, which has provided significant non-dilutive funding for the BX211 program.
Cash Balance and Funding Outlook
BiomX reported a cash balance of $15.2 million as of June 30, 2025, sufficient to fund operations into the first quarter of 2026.
PHGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PHGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 13, 2025 | $0.56 | $0.50 | -10.71% |
May 15, 2025 | $0.55 | $0.56 | +1.82% |
Mar 25, 2025 | $0.63 | $0.58 | -7.94% |
Nov 14, 2024 | $0.72 | $0.75 | +4.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biomx Inc. (PHGE) report earnings?
Biomx Inc. (PHGE) is schdueled to report earning on Nov 13, 2025, Before Open (Confirmed).
What is Biomx Inc. (PHGE) earnings time?
Biomx Inc. (PHGE) earnings time is at Nov 13, 2025, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHGE EPS forecast?
PHGE EPS forecast for the fiscal quarter 2025 (Q3) is -0.3.